首页 | 本学科首页   官方微博 | 高级检索  
     

血清microRNA-506、microRNA-146a对急性淋巴细胞白血病患儿预后不良的预测价值研究
引用本文:陈雨华,高蕾,孙果,包鸿. 血清microRNA-506、microRNA-146a对急性淋巴细胞白血病患儿预后不良的预测价值研究[J]. 中国现代医学杂志, 2023, 0(21): 27-32
作者姓名:陈雨华  高蕾  孙果  包鸿
作者单位:1.江南大学附属儿童医院,检验科,江苏 无锡 214000;2.江南大学附属儿童医院,儿血液科,江苏 无锡 214000
基金项目:江苏省基础研究计划(青年基金)项目(No:BK20210081)
摘    要:目的 探讨血清microRNA-506(miR-506)联合microRNA-146a(miR-146a)对急性淋巴细胞白血病(ALL)患儿预后不良的预测价值。方法 随机选取江南大学附属儿童医院2020年4月—2022年4月收治的76例ALL患儿为研究组,同时选取同期在本院体检的健康儿童80例为对照组。检测并比较所有儿童血清miR-506、miR-146a表达。对研究组患儿进行规范化治疗,并进行为期1年的随访,记录患儿的预后情况,比较不同预后患儿血清miR-506、miR-146a表达。采用多因素逐步Logistic回归模型分析影响患儿预后的危险因素;绘制受试者工作特征(ROC)曲线分析miR-506联合miR-146a对患儿预后的预测价值。结果 研究组miR-506、miR-146a mRNA相对表达量高于对照组(P<0.05)。ALL患儿预后不良发生率为27.63%(21/76)。预后不良患儿miR-506、miR-146a mRNA相对表达量高于预后良好患儿(P<0.05)。预后不良与预后良好患儿的性别、年龄、体质量指数、免疫分型比较,差异均无统计学意义(P>0...

关 键 词:急性淋巴细胞白血病  儿童  microRNA-506  microRNA-146a  预后不良  预测价值
收稿时间:2023-05-24

The value of serum microRNA-506 combined with microRNA-146a in predicting poor prognosis in children with acute lymphoblastic leukemia
Chen Yu-hu,Gao Lei,Sun Guo,Bao Hong. The value of serum microRNA-506 combined with microRNA-146a in predicting poor prognosis in children with acute lymphoblastic leukemia[J]. China Journal of Modern Medicine, 2023, 0(21): 27-32
Authors:Chen Yu-hu  Gao Lei  Sun Guo  Bao Hong
Affiliation:1.Department of Laboratory, Children''s Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, China;2.Department of Pediatric Hematology, Children''s Hospital of Jiangnan University, Wuxi, Jiangsu, 214000, China
Abstract:Objective To investigate the predictive value of serum microRNA-506 (miR-506) in combination with microRNA-146a (miR-146a) for adverse outcomes in children with acute lymphoblastic leukemia (ALL).Methods A total of 76 children with ALL treated at Jiangnan University Children''s Hospital from April 2020 to April 2022 were included in the study group. Simultaneously, 80 healthy children who underwent medical check-ups during the same period were selected as the control group. Serum levels of miR-506 and miR-146a were measured and compared between the two groups. The study group received standardized treatment and was followed up for one year to record the outcomes of the children. The serum levels of miR-506 and miR-146a were compared between children with different outcomes. Multifactorial stepwise logistic regression analysis was used to identify risk factors for children''s outcomes. Receiver Operating Characteristic (ROC) curve analysis was performed to assess the predictive value of miR-506 in combination with miR-146a for children''s outcomes.Results The relative expression levels of miR-506 and miR-146a mRNA were higher in the study group than in the control group (P < 0.05). The rate of adverse outcomes in children with ALL was 27.63% (21/76). Children with adverse outcomes had higher relative expression levels of miR-506 and miR-146a mRNA compared to children with good outcomes (P < 0.05). There were no statistically significant differences in gender, age, body mass index, and immunophenotype between children with adverse and good outcomes (P > 0.05). However, a higher proportion of children with adverse outcomes were classified as high risk, and a higher proportion had an initial white blood cell count above 100×109/L (P < 0.05). Multifactorial stepwise logistic regression analysis showed that miR-506 [O^R = 2.147 (95% CI: 1.294, 3.559) ] and miR-146a [O^R = 2.251 (95% CI: 1.221, 4.149) ] were independent risk factors for adverse outcomes in children with ALL (P < 0.05). ROC curve analysis revealed that miR-506 had a sensitivity of 76.20% (95% CI: 0.143, 0.952) and specificity of 63.60% (95% CI: 0.036, 0.964) in predicting outcomes in children with ALL. miR-146a had a sensitivity of 76.20% (95% CI: 0.095, 0.952) and specificity of 56.40% (95% CI: 0.018, 0.945). When combined, miR-506 and miR-146a had a sensitivity of 90.50% (95% CI: 0.048, 0.962) and specificity of 89.10% (95% CI: 0.018, 0.982) in predicting adverse outcomes in children with ALL.Conclusion High levels of miR-506 and miR-146a are independently associated with adverse outcomes in children with ALL. Moreover, a combination of miR-506 and miR-146a can effectively predict adverse outcomes in children with ALL.
Keywords:acute lymphoblastic leukemia  children  microRNA-506  microRNA-146a  adverse outcomes  predictive value
点击此处可从《中国现代医学杂志》浏览原始摘要信息
点击此处可从《中国现代医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号